Evidence map›Paper›PMID 41145382›Full record

ArticleCancer science2026

Realizing Equitable Precision Oncology via Remote Participation: Japan's First Fully Decentralized Trial (WJOG15221M).

Hiroya Taniguchi, Toshiki Masuishi, Tomoki Sakakida, Takatsugu Ogata, Nobumasa Mizuno, Masashi Ando, Kei Muro, Hidetoshi Hayashi

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroya TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0003-1407-6682
Toshiki MasuishiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Tomoki SakakidaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0003-1913-7923
Takatsugu OgataDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Nobumasa MizunoDepartment of Clinical Research Support Section, Aichi Cancer Center Hospital, Nagoya, Japan.
Masashi AndoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hidetoshi HayashiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-8787-5587

Funding

Japan Agency for Medical Research and Development 23yk0126021h0001Japan Agency for Medical Research and Development 24yk0126028h0001Takeda Oncology
6 · The paper itself

Abstract

WJOG15221M is Japan's first fully remote, investigator-initiated oncology trial, successfully enrolling 28 patients-36% remotely-by integrating trial access into the national CGP program and leveraging existing healthcare infrastructure without new digital tools. Targeting rare ALK fusion-positive tumors, the trial demonstrated that decentralized models can improve equity, efficiency, and continuity of care, offering a scalable path for future precision oncology trials.

Indexed as

Medical OncologyNeoplasmsPrecision MedicineAnaplastic Lymphoma KinaseClinical Trials as TopicFemaleHumansJapanMaleAnaplastic Lymphoma Kinase

Identifiers

PMID41145382
PMCPMC12775560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.